Adding Albumin to Risk Score Improves Mortality Prediction
In patients undergoing transcatheter aortic valve replacement, low albumin tied to higher mortality
This report describes a technique that modifies off-the-shelf endografts to treat iatrogenic type A aortic dissection.
This study compared the midterm outcomes of patients undergoing TAVI with or without previous CABG surgery. Between October 2013 and July 2016, 1,613 patients underwent TAVI according to the Optimized CathEter vAlvular iNtervention (OCEAN)-TAVI registry (previous CABG:n = 120; no previous CABG:n = 1493). The propensity score comprised the variables of the Society of Thoracic Surgeons Score, previous myocardial infarction, peripheral artery disease, chronic kidney disease > stage 2 (estimated glomerular filtration rate
There has been an increase in the need for embolization protection devices as the risk for stroke and other neurological damage from transcatheter aortic valve replacement (TAVR) procedures continues to become more prevalent. Santa Cruz, CA -based Emboline is looking to enter the embolization protection space, which is set to grow from $406 million this year to $605 million by 2023, according to a report from ResearchandMarkets. The emerging medtech company's contribution to the space would come from its Emboliner Embolic Protection Catheter. The Emboliner is a cylindrical mesh filter that completely...
Publication date: Available online 19 April 2018 Source:The Annals of Thoracic Surgery Author(s): Frank A. Baciewicz
Central message: Transcatheter mitral valve replacement may be feasible in the setting of a mechanical aortic prosthesis but non-trivial risks remain.
THE THORACIC AORTA is a significant source for systemic atheroemboli, with mobile atheroma identified as being at higher risk for embolic phenomena.1,2 Transesophageal echocardiography (TEE) is an imaging modality that can provide an accurate and detailed evaluation of the aorta and can be used to assess plaque burden in the perioperative setting.2 –4 This case conference presents a challenging case of mitral valve surgery and coronary artery bypass grafting that was complicated by severe aortic atheroma and low cardiac output syndrome after cardiopulmonary bypass.
WITH MORE THAN a decade of experience with transcatheter aortic valve replacement (TAVR), structural heart teams have seen significant advancements in device technology and several changes in patient management along the way. The option for TAVR began with “inoperable” patients, then included high-risk patients, and finally expanded to intermediate-risk patients. More recently, trials examining outcomes in low-risk patients (Society of Thoracic Surgeons score
AN 87-YEAR OLD male presented with worsening dyspnea on exertion, angina, and new onset atrial tachyarrhythmias. On subsequent workup, severe aortic stenosis was found. Given the patient ’s age, frailty, and severe medical comorbidities, he was deemed to have prohibitive surgical risk and was referred for transcatheter aortic valve replacement (TAVR).
Emboline said today that it pulled in a $10 million Series B round for the namesake embolic protector it’s developing for heart valve replacement procedures. The Emboliner catheter is designed to prevent blood clots from passing into the cerebral vasculature during transcatheter aortic valve replacements. Santa Cruz, Calif.-based Emboline said the round includes $3 million from a consortium led by SV Tech Ventures and Shangbay Capital and $7 million in already-issued convertible notes. The cash is earmarked for Emboline’s SafePass clinical trial, submission for CE Mark approval and initial commerciali...